Risk Information “Window” Proposed By FDA For DTC Print Ads
Executive Summary
A "risk information window" with bullet points is being proposed by FDA as an alternative to presentation of adverse events and warnings in the text of prescription drug direct-to-consumer ads
You may also be interested in...
“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study
FDA will narrow the focus of subsequent studies examining the "brief summary" of risk information in print drug ads to focus on one medical condition following preliminary results from the first study, which considered three different conditions
“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study
FDA will narrow the focus of subsequent studies examining the "brief summary" of risk information in print drug ads to focus on one medical condition following preliminary results from the first study, which considered three different conditions
Risk Disclosure In Rx Ad “Brief Summary” To Be Examined By Modified FDA Study
FDA is modifying its upcoming studies of brief summaries in Rx advertising to assess whether changes such as organizing side effects into short- and long-term categories would aid comprehension